Folate pathway polymorphisms: A molecular window into the future of precision medicine

Sir, The recent article by Yadav et al., reporting the association of the MTHFR C677T and MTRR A66G polymorphisms with prostate cancer susceptibility in the North Indian population, presents a timely and clinically relevant contribution to molecular oncology.[1] Their findings reinforce the crucial role of folate-pathway genetics in carcinogenesis and simultaneously open new perspectives on applying precision medicine principles beyond cancer into complex multifactorial diseases. The implications of this research extend far outside the domain of urological malignancies, suggesting that single-gene variations interacting with micronutrient pathways may influence metabolic, neurological, cardiovascular, immunological, and developmental disorders.[2] Folate-mediated one-carbon metabolism governs DNA methylation, nucleotide synthesis, redox homeostasis, and genomic integrity. Disruptions in this tightly regulated system –through dietary insufficiency or genetic polymorphisms – can lead to uracil misincorporation, DNA strand breaks, and epigenetic dysregulation, all of which are fundamental mechanisms driving malignant transformation.[3] These molecular outcomes explain why MTHFR and MTRR variants have been implicated in multiple cancers, including colorectal, gastric, breast, cervical, lung, and pancreatic malignancies. When viewed through the broader lens of molecular medicine, such pathway-level perturbations unify the pathophysiology of disorders traditionally considered unrelated. The observation by Yadav et al. that MTHFR C677T (CT genotype and dominant model) and MTRR A66G (G allele) significantly increase prostate cancer risk in the North Indian cohort further emphasises ethnic and geographic variability in genomic architecture. Such findings underscore the need for region-specific genomic datasets rather than the extrapolation of Western data to Indian populations.[1] Interestingly, their meta-analysis revealed no global association across multiethnic cohorts, highlighting the complexity of gene–environment interactions and the necessity of population-stratified genomic interpretations. This variability highlights where precision medicine becomes essential. Molecular medicine requires integrating genetic polymorphisms, dietary patterns, epigenetic signatures, microbiome profiles, and environmental exposures. India’s extensive genetic diversity calls for indigenous molecular datasets to prevent misclassification of risk, inappropriate supplementation, or suboptimal therapeutic choices. For example, individuals with MTHFR risk alleles poorly convert folic acid into its active form and may face adverse effects from standard supplementation protocols.[4] Therefore, precision nutrition must replace traditional “one-size-fits-all” dietary advice. The significance of such genetic insights extends to a broad spectrum of chronic diseases. Polymorphisms within the folate cycle are associated with neural tube defects, cardiovascular disease, stroke, neurodegeneration, psychiatric disorders, metabolic syndrome, and immune dysregulation.[5] Integrating molecular signatures into clinical practice could enable early identification of at-risk individuals and guide tailored nutritional, pharmacological, and lifestyle-based interventions. Furthermore, vitamins and micronutrients are increasingly recognized as molecular modulators influencing gene expression, mitochondrial functioning, inflammatory pathways, and tumor microenvironment behavior. For instance, high-dose Vitamin C can modulate redox signalling and improve chemotherapeutic response in certain tumors; Vitamin D can regulate immune cell maturation and transcriptional programs through VDR-dependent chromatin remodelling; and B-Vitamins drive one-carbon metabolism, thereby influencing global methylation patterns.[6] These effects highlight the vast untapped potential of using micronutrient-gene–gene interactions as therapeutic tools. The rapid growth of technologies such as whole-genome sequencing, single-cell omics, metabolomics, and artificial intelligence-based predictive analytics further accelerates the shift toward personalized disease modeling. Single-cell methylation atlases could reveal how MTHFR/MTRR variants affect cellular heterogeneity within tumors, influencing resistance or progression. Deep-learning algorithms can integrate biochemical, dietary, genetic, and clinical data to generate risk prediction scores for cancer, cardiovascular disease, and metabolic disorders. Such integrative models can be applied not only to oncology but also to neurodegeneration, autoimmunity, reproductive medicine, and ageing biology. For example, hyperhomocysteinemia – frequently linked to MTHFR variants – is associated with cognitive decline and endothelial dysfunction. Targeted correction of biochemical derangements guided by genetic profiling could constitute a low-cost, high-impact strategy for prevention in resource-limited settings. In this context, the research conducted by Yadav et al. is not merely a singular genetic association finding; it functions as a framework for utilizing molecular data to guide disease prevention and tailored treatment approaches among diverse populations. The study emphasizes the necessity for comparable molecular research in other Indian subpopulations and disease groups by showcasing population-specific differences in folate-pathway polymorphisms. Furthermore, combining these findings with clinical factors, inflammatory biomarkers, imaging indicators, and multiomics technologies will promote the creation of precision-based risk models. In conclusion, folate-pathway polymorphisms represent not merely a cancer-specific biological phenomenon but also a molecular axis that intersects diverse physiological and pathological states. As India builds its precision medicine ecosystem, integrating genomic profiling, nutrigenomic signatures, and molecular biomarkers into routine clinical practice will prove transformative. The work published in your esteemed journal exemplifies the direction in which molecular medicine is evolving – toward personalized, predictive, preventive, and participatory care. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.